All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

Induction and post-remission treatment strategies for a fit, newly diagnosed patient with NPM1/DNMT3A co-mutated AML

Jan 30, 2023
Share:
Learning objective: After reading this article, learners will be able to cite an appropriate treatment strategy for patients with NPM1/ DNMT3A co-mutated AML.

During the AML Hub Steering Committee meeting in November 2022, key opinion leaders met to discuss induction and post-remission treatment strategies for fit, newly diagnosed patients with NPM1/DNMT3 co-mutated acute myeloid leukemia (AML).

The recorded discussion was chaired by Lars Bullinger, and featured Uwe Platzbecker, Gunnar Juliusson, Gert Ossenkoppele, and Agnieszka Wierzbowska.

Induction and post-remission treatment strategies for a fit, newly diagnosed patient with NPM1/DNMT3A co-mutated AML

Bullinger begins by outlining the recent changes to the World Health Organization classification of AML, and the International Consensus Classification, as well as the updated risk stratification described in the European LeukemiaNet recommendations. Bullinger goes on to discuss the findings of the HARMONY project, looking at NPM1 mutations within clinically significant co-mutational patterns. The steering committee members then consider how these new data may influence treatment decisions within this patient group and conclude by weighing up the benefits and indications for transplant or the monitoring of minimal residual disease, depending on the nature of the mutations present.